Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Sponsor
Holy Name Medical Center, Inc. (Other)
Overall Status
Unknown status
CT.gov ID
NCT03424733
Collaborator
Biogen (Industry)
50
1
2
32.2
1.6

Study Details

Study Description

Brief Summary

Some of the most common side effects of the multiple sclerosis drug Plegridy (pegylated interferon beta-1a) include flu-like symptoms and injection site reactions. Physicians often advise patients to take Tylenol or aspirin prior to injection, but in this study the investigators evaluated whether using a low dose of oral steroid in combination with Tylenol reduced flu-like symptoms and injection site reactions.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Multiple Sclerosis (MS) is a chronic neurological disease characterized by demyelination of the brain and spine. Currently, there are several treatments designed to decrease the frequency of attacks and delay disease progression. One of these treatments, interferon beta, has shown the potential to decrease relapse rates by approximately 30%, but because the body quickly clears these proteins, patients require more frequent dosing. Another interferon therapy called pegylated interferon beta-1a (Plegridy) was released and it was shown to last longer in the body than interferon beta-1a. This is why Plegridy can be take by an injection into tissue under the skin once every 14 days. However, some of the most common side effects of interferon beta therapy include flu-like symptoms and injection skin reactions, which can often cause patients to want to stop treatment. Clinical practitioners often advise patients to take acetaminophen (Tylenol) or aspirin before the injection in order to prevent the onset or decrease the severity of flu-like symptoms. A previous study with patients taking interferon beta-1a showed that taking a low dose oral steroid (prednisone) in addiction to a medication like Tylenol reduced flu-like symptoms compared to just taking Tylenol by itself. Because Plegridy lasts longer in the body and has more convenient dosing for patients, researchers in this study decided to investigate whether taking prednisone in addition to acetaminophen before the injection would help decrease or prevent the occurrence of flu-like symptoms and injection site reactions in patients taking the therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Patients in both arms first take Tylenol and then take Tylenol in combination with Prednisone.Patients in both arms first take Tylenol and then take Tylenol in combination with Prednisone.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a
Actual Study Start Date :
Sep 25, 2017
Anticipated Primary Completion Date :
May 1, 2020
Anticipated Study Completion Date :
May 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Current Plegridy Users

Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.

Drug: Plegridy
Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
Other Names:
  • Pegylated Interferon beta-1a
  • Drug: Prednisone
    Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.

    Drug: Tylenol Pill
    Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
    Other Names:
  • Acetaminophen
  • Experimental: New Plegridy Users

    Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.

    Drug: Plegridy
    Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
    Other Names:
  • Pegylated Interferon beta-1a
  • Drug: Prednisone
    Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.

    Drug: Tylenol Pill
    Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
    Other Names:
  • Acetaminophen
  • Outcome Measures

    Primary Outcome Measures

    1. Flu-like symptoms [12 to 16 weeks]

      Reduced flu-like symptoms from Plegridy injections due to taking both Tylenol and Prednisone prior to treatment. Flu-like symptoms are measured every 6 hours for 48 hours after injection by patients self reporting their muscle aches, temperature, chills, and fatigue on a Holy Name administered Flu-like symptom questionnaire.

    Secondary Outcome Measures

    1. Injection site reactions [12 to 16 weeks]

      Reduced injection site reactions from Plegridy injections due to taking both Tylenol and Prednisone prior to injection. Injection site reactions are reported to a clinical research assistant approximately one week after injection. If present, patients must record their injection site reactions using a Holy Name administered tape measurer in centimeters, as well as descriptive characteristics of the injection (location on body, swelling, redness, itching, and pain). The clinical research assistant records all of the data on an injection site reaction form.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) score
    Exclusion Criteria:
    • prior allergic reaction to interferon products, congestive heart failure, elevated liver enzymes

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Holy Name Medical Center Teaneck New Jersey United States 07666

    Sponsors and Collaborators

    • Holy Name Medical Center, Inc.
    • Biogen

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mary Ann Picone, MD, Neurologist, Holy Name Medical Center, Inc.
    ClinicalTrials.gov Identifier:
    NCT03424733
    Other Study ID Numbers:
    • US-PEG-16-10990
    First Posted:
    Feb 7, 2018
    Last Update Posted:
    Aug 15, 2019
    Last Verified:
    Aug 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Mary Ann Picone, MD, Neurologist, Holy Name Medical Center, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2019